<?xml version="1.0" encoding="UTF-8"?><ns2:project xmlns:ns1="http://gtr.rcuk.ac.uk/gtr/api" xmlns:ns2="http://gtr.rcuk.ac.uk/gtr/api/project" xmlns:ns3="http://gtr.rcuk.ac.uk/gtr/api/fund" xmlns:ns4="http://gtr.rcuk.ac.uk/gtr/api/person" xmlns:ns5="http://gtr.rcuk.ac.uk/gtr/api/project/outcome" xmlns:ns6="http://gtr.rcuk.ac.uk/gtr/api/organisation" ns1:created="2026-07-08T08:44:08Z" ns1:href="http://gtr.ukri.org/gtr/api/projects/384F0D7E-133F-48A7-A539-AB6D0D9513E4" ns1:id="384F0D7E-133F-48A7-A539-AB6D0D9513E4"><ns1:links><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/persons/847E8CC1-EA94-4321-8287-A4F1FAB29819" ns1:rel="PM_PER"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/049789EC-6897-4883-B7EF-F0CBE926AE30" ns1:rel="LEAD_ORG"/><ns1:link ns1:href="http://gtr.ukri.org/gtr/api/organisations/049789EC-6897-4883-B7EF-F0CBE926AE30" ns1:rel="PARTICIPANT_ORG"/><ns1:link ns1:end="2026-04-29T23:00:00Z" ns1:href="http://gtr.ukri.org/gtr/api/funds/80D43742-CA71-4F88-87E4-F62D871F7FF6" ns1:rel="FUND" ns1:start="2025-11-01T00:00:00Z"/></ns1:links><ns2:identifiers><ns2:identifier ns2:type="RCUK">10173224</ns2:identifier></ns2:identifiers><ns2:title>Quantum-Enhanced Photonic-Semiconductor Platform for Sensitive Detection of Misfolded Proteins in Neurodegenerative Diseases</ns2:title><ns2:status>Closed</ns2:status><ns2:grantCategory>Fast Start Response</ns2:grantCategory><ns2:leadFunder>Innovate UK</ns2:leadFunder><ns2:abstractText>**Project title: Quantum-Enhanced Photonic-Semiconductor Platform for Sensitive Detection of Misfolded Proteins in Neurodegenerative Diseases**

Our project introduces a pioneering diagnostic platform combining semiconductors, AI, quantum technologies, and engineering biology. It detects unique protein fingerprints from a simple liquid sample to provide a diagnosis in **under 5 min** for neurodegenerative diseases like Alzheimer's and Parkinson's using the photonic-semiconductor sensor.

These diseases are a growing crisis costing the UK economy over **&amp;pound;45B annually**, with current diagnostic processes taking up to **2 years,** a critical delay that limits treatment options. Our technology tackles this challenge by providing the ultra-high sensitivity needed to spot the disease at its earliest molecular stages.

Aligned with the NHS Long-Term Plan, this platform aims to transform patient care through early, personalised interventions. By providing a faster, more accessible diagnostic tool, we can accelerate the development of new therapies, improve patient outcomes, and reduce the significant societal burden of these devastating conditions.</ns2:abstractText></ns2:project>